VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
USPHU.S. Physical Therapy, Inc.
$68.78$1.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksUSPHFinancials

U.S. Physical Therapy, Inc. (USPH) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly volatile, ranging from a 2.4% contraction in 2025Q3 to a 16.6% expansion in 2024Q4, while gross margins struggle to stabilize above the 20% threshold.

USPH Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue695.26M780.99M671.35M604.8M553.14M495.02M422.97M481.97M453.91M414.05M356.55M331.3M305.07M264.06M252.09M237.01M211.23M201.41M187.69M151.69M135.19M132.12M118.31M105.57M94.74M80.95M63.22M49.94M44M38.8M32.2M
Revenue Growth %4.05%16.33%11%9.34%11.74%17.04%-12.24%6.18%9.63%16.13%7.62%8.6%15.53%4.75%6.36%12.2%4.88%7.31%23.73%12.2%2.33%11.68%12.07%11.43%17.04%28.04%26.61%13.49%13.4%20.5%29.32%
Cost of Goods Sold542.15M623.65M547.42M483.29M441.12M377.84M328.52M369.5M352.25M323.43M274.53M252.94M228.91M199.36M189.5M172.51M151.82M146.24M140.08M114.33M99.35M96.21M85.28M74.6M64.53M54.88M42.9M34.09M30.8M27.3M22.1M
COGS % of Revenue-79.85%81.54%79.91%79.75%76.33%77.67%76.66%77.6%78.11%77%76.35%75.03%75.5%75.17%72.79%71.87%72.61%74.64%75.37%73.49%72.82%72.08%70.67%68.11%67.8%67.86%68.27%70%70.36%68.63%
Gross Profit153.11M157.34M123.92M121.51M112.02M117.18M94.45M112.47M101.66M90.62M82.01M78.36M76.17M64.7M62.59M64.49M59.42M55.17M47.6M37.36M35.84M35.91M33.03M30.96M30.21M26.07M20.32M15.84M13.2M11.5M10.1M
Gross Margin %22.02%20.15%18.46%20.09%20.25%23.67%22.33%23.34%22.4%21.89%23%23.65%24.97%24.5%24.83%27.21%28.13%27.39%25.36%24.63%26.51%27.18%27.92%29.33%31.89%32.2%32.14%31.73%30%29.64%31.37%
Gross Profit Growth %-26.97%1.98%8.47%-4.4%24.07%-16.02%10.63%12.19%10.49%4.66%2.88%17.72%3.38%-2.96%8.54%7.7%15.9%27.41%4.24%-0.19%8.72%6.68%2.5%15.88%28.27%28.27%20.02%14.78%13.86%34.67%
Operating Expenses68.36M76.91M60.71M69.45M55.22M46.53M42.04M45.05M41.35M35.89M32.48M31.07M30.4M25.93M24.78M28.56M26.23M26.74M23.73M17.33M17.25M17.03M17.04M13.97M11.33M9.12M9.94M8.58M7.7M6.7M6.5M
OpEx % of Revenue-9.85%9.04%11.48%9.98%9.4%9.94%9.35%9.11%8.67%9.11%9.38%9.96%9.82%9.83%12.05%12.42%13.28%12.64%11.42%12.76%12.89%14.4%13.23%11.96%11.27%15.72%17.18%17.5%17.27%20.19%
Selling, General & Admin17.48M058.29M046.11M46.53M42.04M45.05M41.35M35.89M32.48M31.07M30.4M25.93M24.78M24.78M22.99M23.39M23.73M17.33M17.25M16.43M16.8M13.97M11.33M9.12M7.61M6.49M5.6M4.8M4.8M
SG&A % of Revenue--8.68%-8.34%9.4%9.94%9.35%9.11%8.67%9.11%9.38%9.96%9.82%9.83%10.45%10.88%11.62%12.64%11.42%12.76%12.43%14.2%13.23%11.96%11.27%12.03%12.99%12.73%12.37%14.91%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses2.21M76.91M2.42M69.45M9.11M00000000003.79M3.24M3.35M000604K238K0002.33M2.09M2.1M1.9M1.7M
Operating Income86.75M80.43M63.21M52.06M56.8M70.65M52.41M67.42M60.31M54.73M49.53M47.29M45.77M38.77M37.8M35.93M33.19M28.43M23.88M20.04M18.6M18.88M15.99M17M18.87M16.95M10.38M7.27M5.5M4.8M3.6M
Operating Margin %12.48%10.3%9.42%8.61%10.27%14.27%12.39%13.99%13.29%13.22%13.89%14.28%15%14.68%15%15.16%15.71%14.11%12.72%13.21%13.76%14.29%13.52%16.1%19.92%20.94%16.42%14.55%12.5%12.37%11.18%
Operating Income Growth %-27.24%21.42%-8.34%-19.6%34.79%-22.26%11.79%10.21%10.49%4.73%3.33%18.05%2.56%5.21%8.26%16.76%19.06%19.17%7.74%-1.52%18.07%-5.91%-9.94%11.36%63.21%42.91%32.11%14.58%33.33%125%
EBITDA109.28M102.82M81.89M67.76M71.54M82.24M62.95M77.52M70.07M64.44M58.31M55.25M52.51M44.33M43.09M41.38M38.86M34.32M29.84M25.02M23.09M23.19M20.32M20.59M21.83M19.51M12.71M9.36M7.6M6.7M5.3M
EBITDA Margin %15.72%13.17%12.2%11.2%12.93%16.61%14.88%16.08%15.44%15.56%16.35%16.68%17.21%16.79%17.09%17.46%18.4%17.04%15.9%16.5%17.08%17.55%17.17%19.5%23.04%24.11%20.11%18.74%17.27%17.27%16.46%
EBITDA Growth %28.64%25.56%20.87%-5.29%-13.01%30.65%-18.8%10.63%8.74%10.51%5.55%5.21%18.44%2.88%4.13%6.49%13.21%15.02%19.27%8.36%-0.44%14.16%-1.33%-5.69%11.86%53.47%35.9%23.11%13.43%26.42%60.61%
D&A (Non-Cash Add-back)22.52M22.39M18.68M15.7M14.74M11.59M10.53M10.1M9.76M9.71M8.78M7.95M6.74M5.56M5.29M5.45M5.67M5.9M5.97M4.99M4.49M4.31M4.32M3.59M2.96M2.57M2.33M2.09M2.1M1.9M1.7M
EBIT82.14M87.27M68.22M58.68M61.35M74.14M67.15M72.98M62.25M54.82M49.63M47.38M45.79M38.78M38.41M36.87M33.78M28.26M24.14M20.04M18.6M20.53M16.5M16.94M18.79M16.95M10.38M7.27M5.5M4.8M3.6M
Net Interest Income-9.87M-9.35M-4.07M-5.53M-5.78M-942K-1.49M-2.03M-1.95M-20.97M-11.38M-7.16M-7.44M-531K-551K4.95M350K-344K-282K-28K332K361K146K-189K-214K-266K-780K0-700K0-700K
Interest Income97K105K3.94M3.77M00142K46K93K88K93K81K18K7K6K5.45M586K8K260K273K332K361K146K00000000
Interest Expense9.97M9.46M8.02M9.3M5.78M942K1.63M2.08M2.04M21.06M11.48M7.24M7.45M538K557K496K236K352K542K301K000189K214K266K780K727K700K0700K
Other Income/Expense-15.71M-2.62M-3M-2.69M-1.23M2.55M13.1M3.48M-103K-20.97M-11.38M-7.16M-1.07M-531K52K446K350K-344K-282K-5.75M-5.35M-5.61M-366K-5.16M-5.06M-5.45M-4.25M-3.3M-2.8M-2.3M-1.9M
Pretax Income71.05M77.81M60.21M49.38M55.57M73.2M65.51M70.91M60.21M33.76M38.15M46.34M44.7M38.24M37.25M40.88M33.54M28.08M16.51M14.28M13.25M14.3M10.78M11.78M13.72M11.5M6.14M3.96M2.7M2.5M1.7M
Pretax Margin %10.22%9.96%8.97%8.16%10.05%14.79%15.49%14.71%13.26%8.15%10.7%13.99%14.65%14.48%14.78%17.25%15.88%13.94%8.8%9.41%9.8%10.82%9.11%11.16%14.49%14.21%9.71%7.93%6.14%6.44%5.28%
Income Tax18.36M19.81M14.61M12.16M12.16M15.27M13.02M13.65M11.37M6.03M11.88M14.65M14.27M12.24M11.03M11.1M8.84M8.11M6.5M5.46M5.06M5.51M4.1M4.45M5.24M4.43M2.4M1.57M1.1M100K100K
Effective Tax Rate %25.83%25.46%24.26%24.62%21.89%20.86%19.88%19.25%18.88%17.87%31.14%31.62%31.93%32%29.62%27.15%26.36%28.88%39.4%38.27%38.17%38.53%38.03%37.78%38.15%38.53%39.15%39.58%40.74%4%5.88%
Net Income10.55M15.06M26.46M14.67M28.27M27.82M30.56M28.15M10.1M22.26M20.55M22.28M19.77M12.72M17.93M20.97M15.64M11.77M10M8.89M6.3M8.79M6.68M7.33M8.49M7.07M3.73M2.39M1.6M2.4M1.6M
Net Margin %1.52%1.93%3.94%2.43%5.11%5.62%7.23%5.84%2.23%5.38%5.76%6.72%6.48%4.82%7.11%8.85%7.41%5.84%5.33%5.86%4.66%6.65%5.64%6.94%8.96%8.74%5.91%4.79%3.64%6.19%4.97%
Net Income Growth %-64.54%-43.08%80.32%-48.09%1.61%-8.97%8.58%178.59%-54.61%8.3%-7.76%12.71%55.36%-29.05%-14.5%34.06%32.96%17.62%12.51%41.23%-28.38%31.64%-8.91%-13.63%20.04%89.32%56.02%49.63%-33.33%50%128.57%
Net Income (Continuing)52.69M58.01M45.6M37.22M43.41M57.92M52.49M57.26M48.84M27.72M26.27M26.49M30.42M26M26.64M29.78M24.7M19.97M17.09M8.81M8.19M9.18M12.04M7.33M8.49M7.07M3.73M2.39M1.6M2.4M1.6M
Discontinued Operations0000000000000-4.77M0000000-387K000000000
Minority Interest313.9M293.31M270.12M176.04M168.78M156.84M133.81M139.19M134.87M104.1M70.33M39.17M28.31M26.83M17.34M14.53M12.43M4.87M6.21M5.65M3.87M3.02M3.31M3.28M3.02M3.25M2.86M2.38M1.7M1.6M1M
EPS (Diluted)0.701.421.841.283.344.494.094.490.801.761.641.771.621.051.511.751.321.000.830.750.540.730.540.610.670.550.110.110.050.070.05
EPS Growth %-77.06%-22.83%43.75%-61.68%-25.61%9.78%-8.91%461.25%-54.55%7.32%-7.34%9.26%54.29%-30.46%-13.71%32.58%32%20.48%10.67%38.89%-26.03%35.19%-11.48%-8.96%21.82%400%0%135.55%-36.38%43.64%130.18%
EPS (Basic)-1.421.841.283.344.494.094.490.801.761.641.771.621.051.521.781.341.010.840.750.540.740.560.660.770.700.130.120.050.080.05
Diluted Shares Outstanding15.17M15.18M15.06M14.19M12.98M12.9M12.84M12.76M12.67M12.57M12.5M12.39M12.22M12.08M11.9M11.98M11.87M11.81M12.05M11.72M11.69M12.04M12.37M12.02M12.67M12.86M10.7M9.85M10.83M10.84M10.55M
Basic Shares Outstanding15.17M15.18M15.06M14.19M12.98M12.9M12.84M12.76M12.67M12.57M12.5M12.39M12.22M12.06M11.8M11.81M11.64M11.7M11.91M11.64M11.69M11.92M11.93M11.11M11.02M10.1M9.56M9.85M10.83M10.84M10.55M
Dividend Payout Ratio-181.66%100.3%164.43%75.42%67.45%13.45%51.71%115.45%45.23%41.41%33.44%29.71%38.03%50.28%18.07%-80.21%72.92%------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Labor cost inflation pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Exhibits Volatile Patterns

According to recent financial disclosures, USPH's revenue growth has fluctuated significantly, ranging from a 2.4% contraction in 2025Q3 to a 16.6% expansion in 2024Q4, suggesting that the company's top-line trajectory remains highly sensitive to both acquisition timing and the inherent variability of patient visit volumes.

The inconsistent revenue growth profile appears to reflect the challenges of integrating new clinic acquisitions while managing a core business dependent on fluctuating referral patterns. Investors should monitor whether the company can achieve more predictable organic growth as it balances its traditional physical therapy operations with the newer Industrial Injury Prevention segment.

Structural Margin Compression Remains Evident

Based on reported figures, USPH's gross margin has struggled to maintain consistency, oscillating between 17.3% and 25.4% over the last ten quarters, which highlights the company's limited ability to absorb rising labor costs within its fixed-reimbursement environment for outpatient physical therapy services.

The narrow net margin, which dipped into negative territory in 2025Q4, suggests that the company's profitability is highly vulnerable to even minor escalations in clinician wages or administrative overhead. This margin volatility warrants further investigation into the company's pricing power relative to commercial and government payers.

Earnings Quality Impacted by Volatility

As reported in recent income statements, USPH's net income has experienced extreme swings, including a significant loss in 2025Q4, which appears to be exacerbated by the company's partnership accounting structure and the impact of non-controlling interests on the bottom line attributable to shareholders.

The erratic EPS performance, highlighted by the -184.6% growth rate in 2025Q4, suggests that investors should focus on normalized earnings metrics rather than headline net income. The presence of stock-based compensation further complicates the assessment of true operational profitability, requiring careful scrutiny of cash-based versus non-cash expenses.

Sustainability of Partnership Model Challenged

While the partnership model is a core differentiator, the recent financial data suggests that the company's reliance on local clinician equity may not fully insulate it from broader industry headwinds, as evidenced by the inconsistent operating margins observed throughout the 2024-2026 period.

Short-sellers might focus on the potential for margin compression if the company fails to pass through rising labor costs to insurers. The structural complexity of consolidating majority-owned partnerships may also mask underlying operational inefficiencies that could become more pronounced during periods of industry-wide labor shortages.

USPH — Frequently Asked Questions

Quick answers to the most common questions about buying USPH stock.

What was U.S. Physical Therapy, Inc.'s (USPH) revenue in 2025?

For fiscal year 2025, U.S. Physical Therapy, Inc. (USPH) reported total revenue of $781.0M. This represents a 2325.4% increase compared to $32.2M in 1996.

Is U.S. Physical Therapy, Inc. (USPH) profitable?

U.S. Physical Therapy, Inc. (USPH) is profitable, generating $15.1M in net income for the fiscal year ending 2025 with a net profit margin of 1.9%.

What is U.S. Physical Therapy, Inc.'s operating profit margin?

U.S. Physical Therapy, Inc. (USPH) reported an operating income of $80.4M, resulting in an operating profit margin of 10.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is U.S. Physical Therapy, Inc.'s gross profit and gross margin?

U.S. Physical Therapy, Inc. (USPH) generated $157.3M in gross profit for the year, representing a gross profit margin of 20.1%. This demonstrates the company's core pricing power and production efficiency.